New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
February 13, 2025 - The FDA approved Samsung Bioepis’ Xbryk (denosumab-dssb), biosimilar to Amgen’s Xgeva® (denosumab).
Download PDF
Return to publications
